* Solid Biosciences Inc SLDB.OQ SLDB.O is expected
to show a
rise in quarterly revenue when it reports results on May 9
(estimated) for the period ending March 31 2024
* The Charlestown Massachusetts-based company is expected
to
report revenue of $1.208 million, according to the mean estimate
from 6 analysts, based on LSEG data.
* LSEG's mean analyst estimate for Solid Biosciences Inc is
for a
loss of 64 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Solid
Biosciences
Inc is $16.50, above its last closing price of $10.00.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Dec. 31 2023 -1.04 -0.99 -1.00 Missed -1.2
Sep. 30 2023 -1.19 -1.19 -1.05 Beat 11.6
Jun. 30 2023 -1.55 -1.53 -1.25 Beat 18.6
Mar. 31 2023 -2.21 -2.05 -1.50 Beat 26.9
Dec. -1.65 -2.82 Missed -70.7
31 2022
Sep. 30 2022 -2.57 -2.67 -2.71 Missed -1.5
Jun. 30 2022 -3.07 -3.15 -3.30 Missed -4.8
Mar. 31 2022 -2.77 -2.76 -3.30 Missed -19.6
This summary was machine generated May 7 at 12:43 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)